West-cost-2

Ocrevus Consumer Panel Information

Ocrevus® (ocrelizumab), 300mg vial, is a Prescription Medicine used to treat relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). Do not use Ocrevus if: you have had an allergic reaction to Ocrevus or any of the ingredients. Tell your doctor if: you have an infection, or a history of a recurring or long-term infection such as hepatitis B; you are taking or have previously taken medicines which may affect your immune system, such as other medicines for MS; you or your child if they were exposed to Ocrevus during pregnancy, intend to have or have had immunisation with any vaccine; you are allergic to any other medicines or any other substances such as foods, preservatives or dyes; you are pregnant or intend to become pregnant; you are breast feeding or plan to breast feed. Tell your doctor immediately or go to your nearest Accident and Emergency Centre if you notice any of the following; swelling of your face, lips, tongue or throat with difficulty breathing; swelling of other parts of your body; shortness of breath, wheezing or trouble breathing; skin problems including rash, itchiness or hives; fever, flushing or chills; cough, throat irritation or pain; feeling tired; headache; dizziness or light headedness; feeling sick (nausea); fast heartbeat. Tell your doctor, nurse or pharmacist if you notice any of the following common side effects: signs of an infection such as fever or chills, cold sore, shingles or genital sores; stuffy nose or chest; thick mucus in the nose, throat or chest; persistent cough; difficulty sleeping (insomnia); diarrhoea, vomiting and/or stomach cramps (gastroenteritis); skin infections, sinus infections. Ocrevus has risks and benefits. Ask your doctor if Ocrevus is right for you. Use strictly as directed. If symptoms continue or you have side effects, see your healthcare professional. For further information on Ocrevus, please talk to your health professional or visit www.medsafe.govt.nz for Ocrevus Consumer Medicine Information.

Ocrevus is a PHARMAC funded medicine for patients with relapsing multiple sclerosis (RMS) who meet defined criteria. Ocrevus is a PHARMAC funded medicine from 1st October 2023 for patients with primary progressive multiple sclerosis (PPMS) who meet defined criteria. A prescription charge and normal doctor’s fees may apply.

Consumer Panel Version 4. Roche Products (New Zealand) Limited, Auckland. Phone: 0800 656 464. www.roche.co.nz.

All trademarks mentioned herein are protected by law.

Privacy Statement
Legal Statement

© 2023, Roche Products (New Zealand) Ltd, Auckland. For more information about Roche, please visit www.roche.co.nz. This site contains information on Ocrevus which is intended for New Zealand consumers. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or use in the country of your origin. Access to this site is subject to the terms in our Legal and Privacy Statement. You accept these terms by continuing to access this site.

M-NZ-00000073-V5/MR9648/OCT2023 This site was last updated OCT 2023

You are about to leave the site to one that is not controlled or developed by Roche Products (New Zealand) Ltd.

Roche does not endorse or control, the content of any linked websites and if you click on any of those links you agree that Roche has no responsibility or duty to you for anything that happens to you as a result. If the linked site is outside New Zealand’s jurisdiction, the information may not be consistent with New Zealand’s legislation, advertising codes or the relevant New Zealand registered Data Sheet.

Please refer to the Data Sheet or Consumer Medicine Information on the Medsafe website for product information applicable to New Zealand.

Ok Continue Close